Last 7 days
10.1%
Last 30 days
-2.9%
Last 90 days
-13.7%
Trailing 12 Months
-30.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
LYB | 30.6B | 50.5B | -3.22% | -3.85% | 7.86 | 0.61 | 9.27% | -30.76% |
PPG | 26.8B | 17.7B | -1.69% | -0.88% | 24.98 | 1.52 | 5.06% | -28.70% |
IFF | 23.4B | 12.4B | -2.88% | -30.54% | -12.58 | 1.88 | 6.73% | -768.10% |
WLK | 14.8B | 15.8B | -4.59% | -8.06% | 6.6 | 0.94 | 34.10% | 11.51% |
RPM | 11.3B | 7.1B | -4.04% | 4.58% | 21.14 | 1.58 | 13.30% | 17.31% |
MID-CAP | ||||||||
OLN | 7.2B | 9.4B | -5.80% | 3.93% | 5.42 | 0.77 | 5.23% | 2.33% |
AXTA | 5.3B | 4.9B | -1.11% | 17.46% | 26.11 | 1.1 | 10.60% | -27.40% |
NEU | 3.5B | 2.8B | 5.14% | 12.04% | 12.54 | 1.27 | 17.35% | 46.43% |
SXT | 3.1B | 1.4B | -1.30% | -12.11% | 22.29 | 2.18 | 4.11% | 18.65% |
GCP | 2.4B | 999.6M | 1.27% | 44.25% | 215.39 | 2.37 | 3.34% | -90.08% |
SMALL-CAP | ||||||||
WLKP | 809.2M | 1.6B | -3.05% | -13.55% | 10.8 | 0.56 | 31.14% | -22.26% |
AMRS | 441.8M | 258.8M | 8.80% | -69.44% | -1.3 | 1.71 | -27.46% | 18.54% |
FF | 315.5M | 396.0M | -17.60% | -28.26% | 20.74 | 0.8 | 17.84% | -46.38% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -1.5% | 12,440 | 12,627 | 12,635 | 12,417 | 11,656 |
Gross Profit | -2.6% | 4,151 | 4,263 | 4,352 | 4,126 | 3,735 |
S&GA Expenses | -0.6% | 1,768 | 1,778 | 1,801 | 1,757 | 1,749 |
R&D Expenses | -3.7% | 603 | 626 | 637 | 643 | 629 |
EBITDA | -1122.2% | -110 | -9.00 | 2,271 | 2,206 | - |
EBITDA Margin | -1140.1% | -0.01* | 0.00* | 0.54* | 0.18* | - |
Earnings Before Taxes | -7.9% | -1,625 | -1,506 | 779 | 693 | 354 |
EBT Margin | -9.5% | -0.13* | -0.12* | 0.19* | 0.06* | - |
Interest Expenses | 10.2% | 336 | 305 | 296 | 296 | 289 |
Net Income | -6.7% | -1,864 | -1,747 | 644 | 565 | 279 |
Net Income Margin | -8.3% | -0.15* | -0.14* | 0.15* | 0.05* | - |
Free Cahsflow | -2240.0% | -107 | 5.00 | 175 | 643 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 2.5% | 35,407 | 34,537 | 39,304 | 39,747 | 39,658 |
Current Assets | 14.4% | 7,432 | 6,494 | 7,730 | 7,507 | 6,987 |
Cash Equivalents | -10.2% | 483 | 538 | 569 | 657 | 711 |
Inventory | 0.9% | 3,151 | 3,122 | 2,993 | 2,795 | 2,516 |
Net PPE | 3.6% | 4,203 | 4,055 | 4,177 | 4,295 | 4,368 |
Goodwill | 0.4% | 13,355 | 13,305 | 16,071 | 45.00 | 16,414 |
Current Liabilities | 2.8% | 3,728 | 3,626 | 4,720 | 4,032 | 3,633 |
Long Term Debt | - | 10,971 | - | - | - | - |
LT Debt, Current | -70.7% | 512 | 1,749 | 939 | 632 | - |
LT Debt, Non Current | 1.1% | 10,373 | 10,260 | 10,363 | 10,738 | 10,768 |
Shareholder's Equity | 4.7% | 17,684 | 16,887 | 20,293 | 20,965 | 21,082 |
Retained Earnings | -19.5% | 955 | 1,186 | 3,589 | 3,683 | 3,641 |
Additional Paid-In Capital | 0.0% | 19,841 | 19,832 | 19,826 | 19,823 | 19,826 |
Accumulated Depreciation | 0.9% | 1,978 | 1,961 | 1,889 | 1,793 | - |
Shares Outstanding | 0.0% | 255 | 255 | 255 | 255 | 255 |
Minority Interest | -11.8% | 30.00 | 34.00 | 33.00 | 32.00 | 35.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -20.6% | 397 | 500 | 639 | 1,075 | 1,437 |
Share Based Compensation | 4.3% | 49.00 | 47.00 | 52.00 | 52.00 | 54.00 |
Cashflow From Investing | -6.2% | 745 | 794 | -394 | -254 | -18.00 |
Cashflow From Financing | 10.2% | -1,229 | -1,369 | -500 | -994 | -1,304 |
Dividend Payments | 0.6% | 810 | 805 | 795 | 786 | 667 |
72.7%
17.7%
4.6%
Y-axis is the maximum loss one would have experienced if International Flavors & Fragrances was unfortunately bought at previous high price.
3.8%
-1.3%
-6.0%
-4.0%
FIve years rolling returns for International Flavors & Fragrances.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-27 | Neo Ivy Capital Management | new | - | 724,000 | 724,000 | 0.49% |
2023-03-24 | Winder Investment Pte Ltd | reduced | - | 355,243,000 | 2,658,360,000 | 55.66% |
2023-03-23 | MetLife Investment Management, LLC | reduced | -1.6 | 834,158 | 6,980,350 | 0.06% |
2023-03-17 | American Portfolios Advisors | reduced | -64.41 | -164,127 | 61,129 | -% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -12.42 | 4,101 | 266,101 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -4.03 | 4,090,890 | 42,067,900 | 0.05% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 1.49 | 27,000 | 178,000 | -% |
2023-03-03 | Crumly & Associates Inc. | sold off | -100 | -289,000 | - | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | sold off | -100 | - | - | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 47,598 | 47,598 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 12.52% | 31,920,258 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.6% | 21,920,824 | SC 13G/A | |
Feb 14, 2022 | alliancebernstein l.p. | 1.5% | 3,768,731 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 11.89% | 30,267,303 | SC 13G/A | |
Feb 10, 2022 | winder investment pte ltd | 9.9% | 25,109,000 | SC 13G/A | |
Feb 04, 2022 | winder investment pte ltd | 9.9% | 25,109,000 | SC 13D/A | |
Feb 01, 2022 | blackrock inc. | 7.5% | 19,198,319 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 10.03% | 10,730,935 | SC 13G/A | |
Feb 08, 2021 | alliancebernstein l.p. | 7.2% | 7,654,749 | SC 13G/A | |
Feb 08, 2021 | winder investment pte ltd | 10.0% | 25,057,193 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 103.07 12.08% | 154.90 68.44% | 252.44 174.51% | 468.64 409.61% | 712.37 674.65% |
Current Inflation | 93.87 2.08% | 138.54 50.65% | 221.20 140.54% | 403.80 339.10% | 608.26 561.44% |
Very High Inflation | 82.56 -10.22% | 118.89 29.28% | 184.57 100.71% | 329.05 257.82% | 489.37 432.16% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 27, 2023 | 8-K | Current Report | |
Mar 23, 2023 | ARS | ARS | |
Mar 23, 2023 | DEF 14A | DEF 14A | |
Mar 23, 2023 | DEFA14A | DEFA14A | |
Mar 15, 2023 | 3 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Feb 27, 2023 | 10-K | Annual Report | |
Feb 27, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-01 | Clyburn Frank | acquired | - | - | 1,323 | chief executive officer |
2023-03-01 | Clyburn Frank | sold (taxes) | -43,712 | 91.64 | -477 | chief executive officer |
2023-02-19 | Strzelecki Angela | sold (taxes) | -16,918 | 96.13 | -176 | president, pharma solutions |
2023-02-19 | Johnson Jennifer Amy | acquired | - | - | 708 | evp, general counsel |
2023-02-19 | Herriott Simon | sold (taxes) | -17,015 | 96.13 | -177 | president health & biosciences |
2023-02-19 | Johnson Jennifer Amy | sold (taxes) | -28,166 | 96.13 | -293 | evp, general counsel |
2023-02-19 | Herriott Simon | acquired | - | - | 617 | president health & biosciences |
2023-02-19 | Strzelecki Angela | acquired | - | - | 584 | president, pharma solutions |
2023-01-24 | DUCKER MICHAEL L | acquired | - | - | 2,209 | - |
2023-01-03 | Strzelecki Angela | acquired | - | - | 1,341 | president, pharma solutions |
CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net sales | $ 12,440 | $ 11,656 | $ 5,084 |
Cost of goods sold | 8,289 | 7,921 | 2,998 |
Gross profit | 4,151 | 3,735 | 2,086 |
Research and development expenses | 603 | 629 | 357 |
Selling and administrative expenses | 1,768 | 1,749 | 949 |
Restructuring and other charges | 12 | 41 | 17 |
Amortization of acquisition-related intangibles | 727 | 732 | 193 |
Impairment of goodwill | 2,250 | 0 | 0 |
Impairment of long-lived assets | 120 | 0 | 0 |
(Gains) losses on sale of fixed assets | (3) | (1) | 4 |
Operating (loss) profit | (1,326) | 585 | 566 |
Interest expense | 336 | 289 | 132 |
Other income, net | (37) | (58) | (7) |
(Loss) income before taxes | (1,625) | 354 | 441 |
Provision for income taxes | 239 | 75 | 74 |
Net (loss) income | (1,864) | 279 | 367 |
Net income attributable to non-controlling interest | 7 | 9 | 4 |
Net income available to IFF common shareholders | (1,871) | 270 | 363 |
Other comprehensive (loss) income , after tax: | |||
Foreign currency translation adjustments | (904) | (848) | 88 |
Gains (losses) on derivatives qualifying as hedges | 0 | 8 | (9) |
Pension and postretirement liability adjustment | 158 | 115 | (60) |
Other comprehensive (loss) income | (746) | (725) | 19 |
Comprehensive (loss) income | (2,610) | (446) | 386 |
Comprehensive (loss) income attributable to IFF shareholders | $ (2,617) | $ (455) | $ 382 |
Net income per share - basic (in dollars per share) | $ (7.32) | $ 1.11 | $ 3.25 |
Net income per share - diluted (in dollars per share) | $ (7.32) | $ 1.10 | $ 3.21 |
Average number of shares outstanding - basic (in shares) | 255 | 243 | 112 |
Average number of shares outstanding - diluted (in shares) | 255 | 243 | 114 |
CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 483 | $ 711 |
Restricted cash | 10 | 4 |
Receivables: | ||
Trade | 1,871 | 1,952 |
Allowance for doubtful accounts | (53) | (46) |
Inventories | 3,151 | 2,516 |
Assets held for sale | 1,200 | 1,122 |
Prepaid expenses and other current assets | 770 | 728 |
Total Current Assets | 7,432 | 6,987 |
Property, plant and equipment, net | 4,203 | 4,368 |
Goodwill | 13,355 | 16,414 |
Other intangible assets, net | 9,082 | 10,506 |
Operating lease right-of-use assets | 636 | 767 |
Other assets | 699 | 616 |
Total Assets | 35,407 | 39,658 |
Current Liabilities: | ||
Bank borrowings, overdrafts and current portion of long-term debt | 410 | 308 |
Commercial paper | 187 | 324 |
Accounts payable | 1,418 | 1,532 |
Accrued payroll and bonus | 267 | 335 |
Dividends payable | 206 | 201 |
Liabilities held for sale | 212 | 101 |
Other current liabilities | 1,028 | 832 |
Total Current Liabilities | 3,728 | 3,633 |
Other Liabilities: | ||
Long-term debt | 10,373 | 10,768 |
Retirement liabilities | 231 | 385 |
Deferred income taxes | 2,265 | 2,518 |
Operating lease liabilities | 565 | 670 |
Other liabilities | 472 | 462 |
Total Other Liabilities | 13,906 | 14,803 |
Commitments and Contingencies (Note 19) | ||
Redeemable non-controlling interests | 59 | 105 |
Shareholders’ Equity: | ||
Common stock, value, issued | 35 | 35 |
Capital in excess of par value | 19,841 | 19,826 |
Retained earnings | 955 | 3,641 |
Accumulated other comprehensive loss | (2,169) | (1,423) |
Treasury stock, value | (978) | (997) |
Total Shareholders’ Equity | 17,684 | 21,082 |
Non-controlling interest | 30 | 35 |
Total Shareholders’ Equity including non-controlling interest | 17,714 | 21,117 |
Total Liabilities and Shareholders’ Equity | $ 35,407 | $ 39,658 |